Recursion Pharmaceuticals receives FDA clearance for investigational cancer drug REC-1245.

Recursion Pharmaceuticals has received FDA clearance for its Investigational New Drug Application for REC-1245. This drug is a potential first-in-class RBM39 degrader aimed at treating biomarker-enriched solid tumors and lymphoma. This development represents a significant step forward in cancer treatment options.

October 02, 2024
12 Articles

Further Reading